-
Icagen’s CEO and chief scientific officer receive raises
21 Nov 2018 16:40 GMT
… Cunningham may purchase 535,000 shares of common stock, which … Krafte may purchase 120,000 shares of common stock, which also … XRPro Sciences Inc. before joining Icagen. In 2015, XPro Sciences … in 2003, Durham-based Icagen provides research and drug discovery …
-
$1.4 Billion Worldwide Compound Management Industry to 2030 - Outsourcing Services Segment to Maintain Fastest Growth
08 Feb 2023 23:17 GMT
…
Frontier Scientific, Inc.
Hamilton Company
Icagen Corporation
Labcyte, Inc.
TCG Lifesciences … and key competitor percentage market shares
Market presence across multiple geographies …
-
Ligand Reports Third Quarter 2022 Financial Results
07 Nov 2022 21:11 GMT
… Weighted average number of common shares-diluted
17,132
…
16,860
17,187
Add: Shares excluded due to anti-dilutive … weighted average number of common shares-diluted
17,132
… consideration related to Pfenex, Icagen, Crystal, CyDex, and …
-
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
16 Sep 2022 20:52 GMT
… of approximately $60 million. Shares of the combined company … approximately 27.8 million shares of common stock and … prefunded warrants to purchase shares of common stock outstanding … including serving as Chairman of Icagen Inc., Chairman and Chief …
-
Ligand Reports Second Quarter 2022 Financial Results
08 Aug 2022 20:36 GMT
… Weighted average number of common shares-diluted
16,868
…
16,846
17,210
Add: Shares excluded due to anti-dilutive … weighted average number of common shares-diluted
17,058
… consideration related to Pfenex, Icagen, Crystal, CyDex, and …
-
Ligand Reports First Quarter 2022 Financial Results
04 May 2022 20:17 GMT
… Weighted average number of common shares-diluted
16,824
… weighted average number of common shares-diluted
17,193
… consideration related to Pfenex, Icagen, Crystal, CyDex, and … 796,071 potentially dilutive shares.
View source version on …
-
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
17 Feb 2022 22:26 GMT
… and eventual distribution of OmniAb shares to Ligand shareholders. Ligand … average number of common shares - diluted 16,733 … average number of common shares - diluted 17,421 … contingent consideration related to Pfenex, Icagen, Crystal, CyDex and Metabasis …
-
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
17 Feb 2022 21:01 GMT
… eventual distribution of OmniAb shares to Ligand shareholders. … weighted average number of common shares - diluted
16,733
…
17,246
16,185
Add: shares excluded due to anti-dilutive … consideration related to Pfenex, Icagen, Crystal, CyDex and …
-
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
23 Mar 2022 20:17 GMT
… to elect redemption of their shares. Avista has agreed to … received in lieu of fractional shares. Upon the closing of … candidates, as well as the Icagen ion channel technology. Ligand … statement on Form 10 registering shares of OmniAb common stock …
-
Ligand (LGND) Inks Merger Deal With SPAC for OmniAb Spin
24 Mar 2022 16:02 GMT
… by SPAC shareholders.
Ligand’s shares have declined 28.9% so … Ab Initio antigen design technology, Icagen’s ion channel technology and …